Filing Details
- Accession Number:
- 0001104659-23-033335
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-16 16:20:16
- Reporting Period:
- 2023-03-14
- Accepted Time:
- 2023-03-16 16:20:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1711933 | Akoya Biosciences Inc. | AKYA | Laboratory Analytical Instruments (3826) | 475586242 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1857447 | Brian Mckelligon | 100 Campus Drive, 6Th Floor Marlborough MA 01762 | President/Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-03-14 | 5,000 | $0.30 | 165,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-03-14 | 4,774 | $9.14 | 160,226 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-03-14 | 226 | $9.92 | 160,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2023-03-14 | 5,000 | $0.00 | 5,000 | $0.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 333,129 | 2027-11-09 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated May 16, 2022.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.77 to $9.765, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.885 to $10.10, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
- The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment.
Billionaire Hedge Funds
